Renaissance Technologies LLC Purchases 4,164 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Renaissance Technologies LLC boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 140,100 shares of the medical instruments supplier’s stock after acquiring an additional 4,164 shares during the period. Renaissance Technologies LLC owned approximately 0.62% of LeMaitre Vascular worth $11,527,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LMAT. PNC Financial Services Group Inc. lifted its holdings in shares of LeMaitre Vascular by 4.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 11,858 shares of the medical instruments supplier’s stock valued at $673,000 after purchasing an additional 555 shares in the last quarter. Campbell & CO Investment Adviser LLC boosted its holdings in shares of LeMaitre Vascular by 102.7% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 10,802 shares of the medical instruments supplier’s stock valued at $613,000 after buying an additional 5,473 shares during the period. Annex Advisory Services LLC boosted its holdings in shares of LeMaitre Vascular by 105.4% in the fourth quarter. Annex Advisory Services LLC now owns 24,834 shares of the medical instruments supplier’s stock valued at $1,410,000 after buying an additional 12,745 shares during the period. Personal CFO Solutions LLC increased its position in shares of LeMaitre Vascular by 6.4% during the fourth quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock worth $316,000 after acquiring an additional 336 shares in the last quarter. Finally, Ranger Investment Management L.P. raised its holdings in shares of LeMaitre Vascular by 1.5% during the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock worth $51,794,000 after acquiring an additional 13,681 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Down 0.2 %

NASDAQ:LMAT opened at $89.96 on Monday. The stock has a market capitalization of $2.02 billion, a PE ratio of 59.58, a P/E/G ratio of 2.28 and a beta of 0.88. LeMaitre Vascular, Inc. has a 1-year low of $44.27 and a 1-year high of $92.90. The firm has a fifty day simple moving average of $86.84 and a 200 day simple moving average of $78.14.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The company had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same period in the previous year, the business earned $0.37 EPS. LeMaitre Vascular’s revenue for the quarter was up 11.4% compared to the same quarter last year. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were paid a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.71%. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Analyst Ratings Changes

Several research firms have recently weighed in on LMAT. Roth Mkm reaffirmed a “buy” rating and set a $100.00 price objective on shares of LeMaitre Vascular in a research report on Friday, May 31st. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. JMP Securities lifted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 target price for the company. Finally, Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $94.40.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the sale, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO George W. Lemaitre sold 12,976 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total value of $1,116,844.32. Following the transaction, the chief executive officer now owns 1,985,358 shares of the company’s stock, valued at $170,879,763.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,251 shares of company stock valued at $3,714,994. 10.79% of the stock is owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.